A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
NCT #
NCT06039384
Condition(s)
Colorectal Cancer, Lung Cancer (NSCLC), Solid Tumor
Molecular Target(s)
KRAS G12, KRAS G12C, KRAS MUTATION, PD-L1
Drug Classification(s)
Immunotherapy, Molecular Targeted Therapy, Small Molecule Immunotherapy
Agents(s)
INCB099280
Phase(s)
I
Mechanism of Action
INCB099280 is a PD-L1 inhibitor. Adagrasib is a KRAS inhibitor (G12C).
Purpose
- How much of the study s can be given with an acceptable level of side effects
- The effects of the study s (good and bad)
- How much of the study s are absorbed into the blood and how fast they are removed
- How the study s are acting on your body
Location
MCD
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target
Conditions
Publications
24-08
RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein RMC-6236 is a RASMULTI(ON) inhibitor
Molecular Targeted Therapy, Small Molecule
KRAS
Solid Tumor
Yes
24-05
BG-68501 is a CDK2 Inhibitor
CDK2 Inhibitor, Molecular Targeted Therapy
CDK2
Solid Tumor
No
24-01
NM32-2668 is an anti-ROR1/Anti-CD3/Anti-HAS Tri-specific Antibody
Molecular Targeted Therapy, Trispecific Antibodies
ROR1
Breast Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Leiomyosarcoma, liposarcoma, Lung Cancer (NSCLC), Mesothelioma, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Renal Cell Cancer, Skin Cancer/ Melanoma
Yes
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.